Synthetic Blood Substitutes And Blood Products Market Report 2026

Synthetic Blood Substitutes And Blood Products Market Overview

• Synthetic Blood Substitutes And Blood Products market size has reached to $7.6 billion in 2025 • Expected to grow to $15.7 billion in 2030 at a compound annual growth rate (CAGR) of 15.6% • Growth Driver: Impact Of Rising Chronic Disease Prevalence On The Growth Of Market • Market Trend: Advancements In Lab-grown Blood Vessels For Trauma Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Synthetic Blood Substitutes And Blood Products Market?

Synthetic blood substitutes and blood products are advanced medical products designed to mimic the functions of human blood, such as oxygen transport and clotting, to treat patients needing blood transfusions. These products, often developed through biotechnological processes, are crucial for managing blood shortages and providing alternatives for emergencies or patients with specific medical conditions. The main types of synthetic blood substitutes and blood products are perfluorocarbon-based products (PFCs), hemoglobin-based oxygen carriers, synthetic platelets, recombinant factors, and blood expanders. Perfluorocarbon-based products (PFCs) are synthetic oxygen carriers that can dissolve and transport oxygen and carbon dioxide in the bloodstream, acting as blood substitutes in medical treatments. It is used for various applications, such as cardiovascular diseases, anemia, organ transplant, injury and trauma, and other applications. Also, it is used by several end users, including hospitals and clinics, blood banks, and other end users.

What Is The Synthetic Blood Substitutes And Blood Products Market Growth Forecast?

The synthetic blood substitutes and blood products market size is expected to see rapid growth in the next few years. It will grow to $15.7 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to rising trauma cases, aging population surgeries, innovation in recombinant factors, demand for universal blood substitutes, emergency preparedness investments. Major trends in the forecast period include development of oxygen-carrying blood substitutes, emergency trauma blood alternatives, reduced dependence on donor blood, extended shelf-life blood products, military and disaster medicine adoption.

Global Synthetic Blood Substitutes And Blood Products Market Segmentation

1) By Type: Perfluorocarbon Based Product (PFC), Haemoglobin Based Oxygen Carrier, Synthetic Platelet, Recombinant Factor, Blood Expander 2) By Application: Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, Other Applications 3) By End-User: Hospitals And Clinics, Blood Banks, Other End users Subsegments: 1) By Perfluorocarbon Based Product (PFC): Emulsion-Based Products, Non-Emulsion-Based Products 2) By Haemoglobin Based Oxygen Carrier: Polymerized Hemoglobin-Based Products, Crosslinked Hemoglobin-Based Products 3) By Synthetic Platelet: Platelet Substitutes, Platelet Aggregation Inhibitors 4) By Recombinant Factor: Recombinant Factor VIII, Recombinant Factor IX, Other Recombinant Factors 5) By Blood Expander: Colloid Solutions, Crystalloid Solutions

What Is The Driver Of The Synthetic Blood Substitutes And Blood Products Market?

The rising prevalence of chronic diseases is expected to propel the growth of the synthetic blood substitutes and blood products market going forward. Chronic diseases refer to long-lasting conditions that can be controlled but not cured, often persisting for a year or more and requiring ongoing medical attention. The rising prevalence of chronic diseases can be attributed to several factors, including an aging population, unhealthy lifestyles, and increased life expectancy. Synthetic blood substitutes and blood products can play a critical role in managing the prevalence of chronic diseases by addressing specific challenges related to blood loss, anaemia, and organ function, which are common in patients with chronic conditions. For instance, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP recorded type 2 diabetes prevalence in adults as 7.0% for those aged 17 and over in England in March 2024, which was an increase from 6.8% in March 2023. Therefore, the rising prevalence of chronic diseases drives the growth of the synthetic blood substitutes and blood products industry.

Key Players In The Global Synthetic Blood Substitutes And Blood Products Market

Major companies operating in the synthetic blood substitutes and blood products market are Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, Baxter International Inc., Octapharma AG, Green Cross Corporation, Alliance Pharmaceutical Corporation, Hemosol Inc., Sanguine Corporation, Sangart Inc., Biopure Corporation, Tenex Therapeutics, Velico Medical, Hemarina S.A., KaloCyte Inc., Aurum Biosciences Limited, SpheriTech Limited, Dendritech Inc., HbO2 Therapeutics LLC, HemoBioTech Inc., Somatogen Inc.

Global Synthetic Blood Substitutes And Blood Products Market Trends and Insights

Major companies operating in the synthetic blood substitutes and blood products market are focusing on developing innovative products, such as lab-grown blood vessels, to enhance emergency medical care, improve trauma treatment outcomes, and address the global shortage of donor blood and tissues. Lab-grown blood vessels are artificial blood conduits engineered from human or synthetic cells, designed to replicate the structure and function of natural arteries and veins for medical applications such as trauma repair, dialysis, and cardiovascular surgery. For instance, in December 2024, Humacyte Global, Inc., a US-based clinical-stage biotechnology platform company, received US Food and Drug Administration (FDA) approval for Symvess, an off-the-shelf, bioengineered blood vessel implant for trauma patients needing urgent revascularization, offering a safer alternative to vein harvesting or synthetic grafts. Symvess, designed for universal use, restores blood flow and preserves limbs after severe injuries.

What Are Latest Mergers And Acquisitions In The Synthetic Blood Substitutes And Blood Products Market?

In December 2024, GVS S.p.A., an Italy-based plastic fabrication company, acquired blood assets from Haemonetics Corporation for $67.1 million. The acquisition aims to streamline GVS's business focus on plasma and hospital-based blood management solutions and expand its product offerings in the blood collection and filtration market. Haemonetics Corporation is a US-based company that develops and sells blood management devices, including artificial blood substitutes and other blood products.

Regional Outlook

North America was the largest region in the synthetic blood substitutes and blood products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Synthetic Blood Substitutes And Blood Products Market?

The synthetic blood substitutes and blood products market consists of sales of artificial blood substitutes, blood plasma substitutes, and blood plasma products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.